Related Experiment Video
Updated: Apr 11, 2026
12:10
Retzius-Sparing Robot-Assisted Radical Prostatectomy
Published on: May 19, 2022
9.9K
Long-term morbidity after multivisceral resection for retroperitoneal sarcoma
D Callegaro1, R Miceli2, C Brunelli3,4
1Department of Surgery, Pain Therapy and Rehabilitation Unit, Milan, Italy.
The British Journal of Surgery
|June 5, 2015
Summary
Long-term morbidity after retroperitoneal sarcoma surgery is generally low. Severe chronic pain and motor impairment are rare, and kidney function remains stable after nephrectomy.
Area of Science:
- Oncology
- Surgical Oncology
- Sarcoma Research
Background:
- Retroperitoneal sarcomas are rare cancers.
- Surgical resection is a primary treatment for these tumors.
- Long-term outcomes and morbidity after surgery are not well-documented.
Purpose of the Study:
- To evaluate the long-term morbidity in patients who underwent surgery for primary retroperitoneal sarcoma.
- To assess functional outcomes and pain levels in survivors.
- To investigate the impact of nephrectomy on renal function.
Main Methods:
- A cross-sectional study design was employed.
- 95 patients who underwent surgery between 2002 and 2011 were included.
- Morbidity was assessed using clinical interviews, the Lower Extremity Functional Scale (LEFS), and the Brief Pain Inventory--Short Form.
Main Results:
- 76% of patients reported sensory impairment.
- The median LEFS score was 60, indicating moderate limb function.
- Pain intensity scores were generally low, with a mean of 1.23-2.68.
- No significant difference in renal function was observed between patients who had undergone nephrectomy and those who had not.
Conclusions:
- Multivisceral resection for retroperitoneal sarcomas rarely leads to severe chronic pain or lower limb motor impairment.
- Long-term renal function is not significantly affected by nephrectomy in these patients.
